Published in
American Society of Hematology, Blood Advances, 7(4), p. 1265-1269, 2020
DOI: 10.1182/bloodadvances.2019001256
Links
Tools
Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma
Journal article published in 2020 by
Yana Pikman 
,
Amy Saur Conway,
Amanda L. Robichaud,
Samuel Kitara,
Alanna J. Church ,
Alyssa L. Kennedy ,
Lewis B. Silverman,
Amy L. Billett,
David M. Weinstock ,
Marian H. Harris,
Kimberly Stegmaier
,
Amy Saur Conway,
Amanda L. Robichaud,
Samuel Kitara,
Alanna J. Church ,
Alyssa L. Kennedy ,
Lewis B. Silverman,
Amy L. Billett,
David M. Weinstock ,
Marian H. Harris,
Kimberly Stegmaier
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points We report a patient with hepatosplenic T-cell lymphoma (HSTL) and compare the disease to the derived xenograft model. Enhancer of zeste homolog 2 (EZH2) inhibitor treatment of an EZH2-mutant HSTL patient-derived xenograft model led to prolonged survival.